PTPRJ

PTPRJ Full Name

protein tyrosine phosphatase, receptor type, J

PTPRJ Introduction

PTPRJ, also known as protein tyrosine phosphatase receptor type J, is a single‑copy gene mapped to human chromosome 11p11.2, a region frequently associated with loss‑of‑heterozygosity events in various malignancies. The gene spans over 150 kilobases and contains 23 exons, with multiple alternative splice variants that generate distinct protein isoforms differing in their extracellular ectodomains. Its promoter region is rich in CpG dinucleotides and harbors binding sites for transcription factors such as SP1 and ETS‑1, suggesting tight regulation during development and immune activation. Orthologs are present in all vertebrates, with remarkable conservation of the intracellular phosphatase domains, underscoring its fundamental role in metazoan signal transduction.The mature PTPRJ protein is a type I transmembrane glycoprotein composed of an extended extracellular region, a single hydrophobic transmembrane helix, and a cytoplasmic tail bearing a single catalytic protein tyrosine phosphatase domain. The ectodomain contains multiple fibronectin type III‑like repeats and a MAM (meprin/A5/mu) domain, which are implicated in homophilic and heterophilic adhesion events. Notably, its phosphatase domain lacks the canonical phosphotyrosine‑binding pocket loop found in most PTPs, instead employing a unique substrate‑recognition mechanism that favors bulky, hydrophobic residues adjacent to the phosphotyrosine. This structural singularity endows PTPRJ with the capacity to dephosphorylate receptor tyrosine kinases such as PDGFRβ and VEGFR2, as well as Src‑family kinases, making it a pleiotropic negative regulator of growth signals.

Figure1. Structure of PTPRJ.

Enzymatic Properties and Signaling Networks
Biochemically, PTPRJ exhibits a relatively low turnover number compared to cytoplasmic PTPs, but its specificity is sharpened by its ectodomain‑mediated interactions that position it near its substrates. It preferentially dephosphorylates activation‑loop tyrosines of receptor tyrosine kinases, thereby attenuating MAPK/ERK and PI3K/AKT cascades, while concurrently enhancing JAK/STAT signaling in certain immune contexts through dephosphorylation of inhibitory residues. The enzyme is sensitive to oxidative inactivation, as its catalytic cysteine can form a sulfenic acid intermediate, and its activity is further modulated by reversible ubiquitination and proteasomal degradation. This intricate regulatory landscape positions PTPRJ as a node that integrates redox status, adhesion, and growth factor inputs, fine‑tuning cellular decisions between proliferation, differentiation, and quiescence.

Pathophysiological Relevance and Therapeutic Angles
Germline polymorphisms in PTPRJ have been associated with increased susceptibility to colorectal and gastric cancers, and somatic mutations—mostly missense changes in the phosphatase domain—occur in ~5‑10% of sporadic lung adenocarcinomas, often correlating with poorer prognosis. In atherosclerosis, endothelial PTPRJ expression is upregulated by oscillatory shear stress, where it dampens VEGF‑mediated permeability, suggesting a protective role against vascular leakage. Conversely, in chronic myeloid leukemia, reduced PTPRJ activity permits constitutive BCR‑ABL signaling, and experimental restoration of its function sensitizes cells to imatinib. While no direct PTPRJ‑targeted drugs have entered clinical trials, small‑molecule activators and allosteric modulators are under preclinical evaluation, with the major challenge being isoform selectivity given the structural similarity among receptor PTPs.

Alternate Names for PTPRJ

PTPRJ; protein tyrosine phosphatase, receptor type, J; receptor-type tyrosine-protein phosphatase eta; CD148; DEP1; HPTPeta; DEP-1; R-PTP-J; HPTP eta; CD148 antigen